Catalyst Biosciences Inc
CBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$478.1M
Close$
$19.91
30.1% upside
Current Fair Value
30.1% upsideUndervalued by 30.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $478.10 Million |
|---|---|
| Enterprise Value | $293.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-14.78 |
| Beta | 1.19 |
| Outstanding Shares | 30,397,886 |
Return
| Return on Equity | -79.56% |
|---|---|
| Return on Assets | -73.46% |
| Return on Invested Capital | -91.83% |
Valuation & Multiples
| P/E Ratio | -1.59 |
|---|---|
| PEG | 0.31 |
| Price to Sales | -15.31 |
| Price to Book Ratio | 2.55 |
| Enterprise Value to Revenue | -9.94 |
| Enterprise Value to EBIT | -1.73 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
$357,143
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.78
Average shareholder expectationRevenue Estimate
$357,143
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.12%▼ 2.02% |
|---|---|
| Total Invested | $461.27M▲ 63.89% |
| Investors Holding | 60▲ 6.00% |
ESG Score
No data
About Catalyst Biosciences Inc
CEO: Nassim Usman